Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Metastatic Castration-Resistant Prostate Cancer × belzutifan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Metastatic Castration-Resistant Prostate Cancer 1 Kidney Neoplasms 1

Interventions

pembrolizumab 1 olaparib 1 lenvatinib 1 enzalutamide 1 belzutifan 1 Prednisone 1 Etoposide 1 Docetaxel 1 Dexamethasone 1 Carboplatin 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02861573 2026-02-17

KEYNOTE-365

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡